Clinical trials sponsored by Takeda

Phase breakdown

Conditions studied

Recruiting trials led by Takeda

• A Continuation Study of TAK-279 in Adults With Ulcerative Colitis (UC) and Crohn's Disease (CD)
  NCT06764615 · Phase: Phase 2 · Ages: 18 Years to 75 Years · Sex: All (male and female) · 32 locations
• A Long-Term Extension Study of Vedolizumab in Children and Teenagers With Ulcerative Colitis (UC) or Crohn's Disease (CD)
  NCT06405087 · Phase: Phase 3 · Ages: 2 Years to 17 Years · Sex: All (male and female) · 108 locations
• A Long-Term Study of Zasocitinib in Children and Teenagers With Plaque Psoriasis
  NCT07250802 · Phase: Phase 3 · Ages: 4 Years to 17 Years · Sex: All (male and female) · 39 locations
• A Study of Maribavir in Adults With Kidney Failure Who Have a Cytomegalovirus (CMV) Infection After Transplantation
  NCT06243731 · Phase: Not specified · Ages: 18 Years and older · Sex: All (male and female) · 25 locations
• A Study of Vedolizumab Intravenous (IV) and Adalimumab or Vedolizumab and Ustekinumab in Adults With Crohn's Disease
  NCT06045754 · Phase: Phase 4 · Ages: 18 Years to 70 Years · Sex: All (male and female) · 48 locations
• A Study of Vedolizumab SC Given to Adults With Moderate to Severe Ulcerative Colitis or Crohn's Disease in South Korea
  NCT05428345 · Phase: Not specified · Ages: 18 Years and older · Sex: All (male and female) · 2 locations
• A Study of Vedolizumab With Tofacitinib in Adults With Ulcerative Colitis (UC)
  NCT06095128 · Phase: Phase 4 · Ages: 18 Years to 65 Years · Sex: All (male and female) · 46 locations
• A Study of Vedolizumab With and Without Upadacitinib in Adults With Crohn's Disease
  NCT06227910 · Phase: Phase 3 · Ages: 18 Years to 65 Years · Sex: All (male and female) · 138 locations
• A Study of Vedolizumab in Adult Participants With Moderate to Severe Crohn's Disease
  NCT05837897 · Phase: Phase 3 · Ages: 18 Years to 80 Years · Sex: All (male and female) · 41 locations
• A Study of Vedolizumab in Adults With Ulcerative Colitis (UC) or Crohn's Disease (CD) in the Community Setting
  NCT06581328 · Phase: Phase 4 · Ages: 18 Years to 80 Years · Sex: All (male and female) · 202 locations
• A Study of Vedolizumab in Children With Ulcerative Colitis (UC) or Crohn's Disease (CD)
  NCT05442567 · Phase: Phase 3 · Ages: 2 Years and older · Sex: All (male and female) · 196 locations
• A Study of Vedolizumab in Children and Teenagers With Moderate to Severe Crohn's Disease (CD)
  NCT04779320 · Phase: Phase 3 · Ages: 2 Years to 17 Years · Sex: All (male and female) · 96 locations
• A Study of Vedolizumab in Children and Teenagers With Ulcerative Colitis or Crohn's Disease
  NCT06100289 · Phase: Phase 3 · Ages: 2 Years to 17 Years · Sex: All (male and female) · 108 locations
• A Study of Zasocitinib (TAK-279) in Adults With Active Crohn's Disease
  NCT07403968 · Phase: Phase 2 · Ages: 18 Years to 75 Years · Sex: All (male and female) · 1 location
• A Study of Zasocitinib in Adults With Psoriatic Arthritis Who Have Not Taken Biologic Medicines
  NCT06671483 · Phase: Phase 3 · Ages: 18 Years and older · Sex: All (male and female) · 188 locations
• A Study of Zasocitinib in Adults With Psoriatic Arthritis Who Have or Have Not Been Treated With Biologic Medicines
  NCT06671496 · Phase: Phase 3 · Ages: 18 Years and older · Sex: All (male and female) · 123 locations
• A Study on the Safety of TAK-279 and Whether it Can Reduce Inflammation in the Bowel of Participants With Moderately to Severely Active Crohn's Disease
  NCT06233461 · Phase: Phase 2 · Ages: 18 Years to 75 Years · Sex: All (male and female) · 190 locations
• A Survey of Darvadstrocel in People With Crohn's Disease
  NCT05113095 · Phase: Not specified · Ages: 20 Years and older · Sex: All (male and female) · 1 location
• A Trial to Evaluate the Safety and Activity of Fruquintinib in Minority Populations With Advanced, Previously Treated Colorectal Cancer
  NCT06562543 · Phase: Phase 4 · Ages: 18 Years and older · Sex: All (male and female) · 45 locations
• Continuation Study of Zasocitinib in Adults With Psoriatic Arthritis
  NCT07286058 · Phase: Phase 3 · Ages: 18 Years and older · Sex: All (male and female) · 78 locations
• Survey of Brigatinib Used To Treat People With Non-Small Cell Lung Cancer
  NCT05100069 · Phase: Not specified · Ages: No age limits stated · Sex: All (male and female) · 1 location

Common questions

How many trials is Takeda recruiting for?

Takeda is the lead sponsor of 21 recruiting trials.

Is this list complete?

No. For the full record, search ClinicalTrials.gov.